Table 1.
An overview of tumor-stroma ratio studies reporting an inter-observer score
| Study | Number of patients | Stage | Type of cancer | Inter-observer variationa |
|---|---|---|---|---|
| Mesker et al., 2009 [5] | 135 | I–II | Colon cancer | Κ = 0.6–0.7b (3 observers) |
| Courrech Staal et al., 2010 [10] | 93 | I–IV | Esophageal cancer | Κ = 0.84b |
| West et al., 2010 [17] | 145 | I–IV | Colorectal cancer | Κ = 0.97 |
| De Kruijf et al., 2011 [7] | 574 | I–III | Breast cancer | Κ = 0.85b |
| Moorman et al., 2012 [13] | 124 | I–III | Breast cancer | Κ = 0.74b |
| Wang et al., 2012 [15] | 95 | I–III | Esophageal squamous cell cancer | Κ = 0.84b |
| Huijbers et al., 2013 [3] | 710 | II–III | Colon cancer | Κ = 0.89b |
| Dekker et al., 2013 [8] | 403 | I–II | Breast cancer | Κ = 0.80b |
| Downey et al., 2014 [22] | 180 | I–III | Breast cancer (ER+) | Κ = 0.70 |
| Park et al., 2014 [14] | 250 | I–III | Colorectal cancer | Κ = 0.81b |
| Liu et al., 2014 [11] | 184 | I–II | Cervical cancer | Κ = 0.81b |
| Zhang et al., 2014 [19] | 93 | I–IV | Nasopharyngeal cancer | Κ = 0.85b |
| Gujam et al., 2014 [21] | 361 | I–III | Breast cancer | Κ = 0.83b |
| Lv et al., 2015 [12] | 300 | I–IV | Hepatocellular cancer | Κ = 0.87b |
| Pongsuvareeyakul et al., 2015 [23] | 131 | I–II | Cervical | Κ = 0.78b |
| van Pelt et al., 2016 [6] | 102 | III | Colon cancer | Κ = 0.73b |
| Li et al., 2017 [24] | 51 | II–IV | Gallbladder | Κ = 0.85b |
| Roeke et al., 2017 [9] | 737 | I–III | Breast cancer | Κ = 0.68b |
aKappa value
bStudy in which the method described in this paper was used for scoring the TSR